From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Last Updated: Monday, December 12, 2022

Orca-T, a high-precision, immunotherapy consisting of stem and immune cells, reduced GVHD rates in a phase 2 trial of 180 leukemia patients. A phase 3 trial comparing Orca-T to standard of care is currently enrolling patients.

2022 ASH Annual Meeting
Advertisement
News & Literature Highlights
Advertisement
Advertisement